 |
The Journal of Neuroscience, January 19, 2005, 25(3):662-671; doi:10.1523/JNEUROSCI.4166-04.2005
Previous Article | Next Article 
Cellular/Molecular
Transient Receptor Potential Vanilloid Subtype 1 Mediates Cell Death of Mesencephalic Dopaminergic Neurons In Vivo and In Vitro
Sang R. Kim,1,2
Da Y. Lee,1,2
Eun S. Chung,1,2
Uh T. Oh,3
Seung U. Kim,1,2 and
Byung K. Jin1,2
1Brain Disease Research Center and 2Neuroscience Graduate Program, Ajou University School of Medicine, Suwon 442-749, Korea, and 3Sensory Research Group, Creative Research Initiatives, Seoul National University, College of Pharmacy, Seoul 151-742, Korea
Intranigral injection of the transient receptor potential vanilloid subtype 1 (TRPV1; also known as VR1) agonist capsaicin (CAP) into the rat brain, or treatment of rat mesencephalic cultures with CAP, resulted in cell death of dopaminergic (DA) neurons, as visualized by immunocytochemistry. This in vivo and in vitro effect was ameliorated by the TRPV1 antagonist capsazepine (CZP) or iodo-resiniferatoxin, suggesting the direct involvement of TRPV1 in neurotoxicity. In cultures, both CAP and anandamide (AEA), an endogenous ligand for both TRPV1 and cannabinoid type 1 (CB1) receptors, induced degeneration of DA neurons, increases in intracellular Ca2+ ([Ca2+]i), and mitochondrial damage, which were inhibited by CZP, the CB1 antagonist N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) or the intracellular Ca2+ chelator BAPTA/AM. We also found that CAP or AEA increased mitochondrial cytochrome c release as well as immunoreactivity to cleaved caspase-3 and that the caspase-3 inhibitor z-Asp-Glu-Val-Asp-fmk protected DA neurons from CAP- or AEA-induced neurotoxicity. Additional studies demonstrated that treatment of mesencephalic cultures with CB1 receptor agonist (6aR)-trans 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d] pyran-9-methanol (HU210) also produced degeneration of DA neurons and increases in [Ca2+]i, which were inhibited by AM251 and BAPTA/AM. The CAP-, AEA-, or HU210-induced increases in [Ca2+]i were dependent on extracellular Ca2+, with significantly different patterns of Ca2+ influx. Surprisingly, CZP and AM251 reversed HU210- or CAP-induced neurotoxicity by inhibiting Ca2+ influx, respectively, suggesting the existence of functional cross talk between TRPV1 and CB1 receptors. To our knowledge, this study is the first to demonstrate that the activation of TRPV1 and/or CB1 receptors mediates cell death of DA neurons. Our findings suggest that these two types of receptors, TRPV1 and CB1, may contribute to neurodegeneration in response to endogenous ligands such as AEA.
Key words: transient receptor potential vanilloid 1; capsaicin; capsazepine; anandamide; cannabinoid type-1 receptor; dopaminergic neurons
Received June 23, 2004;
revised November 16, 2004;
accepted November 24, 2004.
This article has been cited by other articles:

|
 |

|
 |
 
T. Ohta, T. Imagawa, and S. Ito
Novel Gating and Sensitizing Mechanism of Capsaicin Receptor (TRPV1): TONIC INHIBITORY REGULATION OF EXTRACELLULAR SODIUM THROUGH THE EXTERNAL PROTONATION SITES ON TRPV1
J. Biol. Chem.,
April 4, 2008;
283(14):
9377 - 9387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Starowicz, S. Maione, L. Cristino, E. Palazzo, I. Marabese, F. Rossi, V. de Novellis, and V. Di Marzo
Tonic Endovanilloid Facilitation of Glutamate Release in Brainstem Descending Antinociceptive Pathways
J. Neurosci.,
December 12, 2007;
27(50):
13739 - 13749.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Kim, S. U. Kim, U. Oh, and B. K. Jin
Transient Receptor Potential Vanilloid Subtype 1 Mediates Microglial Cell Death In Vivo and In Vitro via Ca2+-Mediated Mitochondrial Damage and Cytochrome c Release
J. Immunol.,
October 1, 2006;
177(7):
4322 - 4329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hejazi, C. Zhou, M. Oz, H. Sun, J. H. Ye, and L. Zhang
{Delta}9-Tetrahydrocannabinol and Endogenous Cannabinoid Anandamide Directly Potentiate the Function of Glycine Receptors
Mol. Pharmacol.,
March 1, 2006;
69(3):
991 - 997.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|